Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:7/7/2009

ng public health crisis.

Contract manufacturing services:

We recently completed our $22 million manufacturing facility. During the next 3 months, it will be validated for clinical supplies and readied for contract manufacturing. This facility was built to manufacture Multikine for the Phase III trial and sale thereafter. Due to the unique requirements for Multikine, we have developed over the last 10 years a cold fill at this facility which is not available for contract manufacturing anywhere else. This means that we can fill our Multikine into vials in a completely sterile manner not only at room temperature, as everyone else does, but also at 4 degrees Centigrade. For Multikine, this is a critical step since long exposure to room temperature not only "kills" the biological activity of the investigational product, but may also alter the ratios of the biologically active components and therefore change Multikine. Similar needs exist for every other biologic, including stem cell-derived products and biosimilars. Our 4 degree Centigrade cold aseptic fill will be offered to the industry as a contract service. I leave you with one simple thought: how would your life be affected if you did not have a refrigerator or freezer? We believe that the 4 degree Centigrade cold aseptic fill has the same kind of impact on the pharmaceutical/biotechnology drug industry.

Multikine cancer therapy:

We believe that the most critical step the company can take is to enter the pivotal Phase III clinical trial to support marketing applications for Multikine. In published studies, Multikine has been shown to be non-toxic, to increase survival by 33%, and to eliminate the tumor in 12% of the patients after only a 3-week treatment. The recent success of Dendreon with its prostate cancer vaccine has shown that it is possible to stimulate the immune system of cancer patients to increase survival. Dendr
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. CEL-SCI to Present at the Noble Financial Conference
2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
3. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
4. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
5. CEL-SCI Takes Delivery of New Manufacturing Facility
6. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
7. CEL-SCI Corporation Releases Letter to Shareholders
8. CEL-SCI Corporation Announces 2008 Financial Results
9. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
10. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
11. CEL-SCIs L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015   Cypher Genomics, ... Sequenom, Inc. (NASDAQ: SQNM ), the ... agreement for next generation noninvasive prenatal tests (NIPT). ... interpretation technology, called Mantis™, to advance analysis of ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... GMO corn cases filed across the United States, and ... being consolidated in a Kansas federal court for pretrial proceedings. ... Corn Litigation, MDL No. 2591 in the U.S. District Court ... GMO corn multidistrict litigation (MDL) has been handed over to ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 23, 2014 ... mercaptan such as its definition, classification, application and ... manufacturing process, and product cost structure. Production is ... also covers upstream raw materials, equipment, downstream client ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... 27 Alfacell Corporation (OTC Bulletin Board: ACEL) today ... the U.S. Food and Drug Administration (FDA) to discuss ... the ONCONASE rolling New Drug Application (NDA) for the ... the pre-NDA meeting, the FDA provided guidance to the ...
... for Tuesday, February 3, 2009 SAN DIEGO, Jan. 27 ... announced today that the Company will report its fourth ... market closes on Tuesday, February 3, 2009. Neurocrine will ... discuss its financial results and provide a Company update ...
... in Shortest Period of TimeWASHINGTON, Jan. 27 ... in targeted therapies that utilize personalized medicine to ... by the Deloitte Center for Health Solutions found ... to produce a positive return on investment across ...
Cached Biology Technology:Alfacell Provides ONCONASE(R) NDA Submission Update 2Alfacell Provides ONCONASE(R) NDA Submission Update 3Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results 2Adoption of Personalized Medicine May Yield Significant ROI; Time to Achieve Benefit Varies Among U.S. Health Care Stakeholders, According to Deloitte Report 2Adoption of Personalized Medicine May Yield Significant ROI; Time to Achieve Benefit Varies Among U.S. Health Care Stakeholders, According to Deloitte Report 3Adoption of Personalized Medicine May Yield Significant ROI; Time to Achieve Benefit Varies Among U.S. Health Care Stakeholders, According to Deloitte Report 4
(Date:12/19/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) ... Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition ... reading feature with the iPhone 5S. It is currently ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ...
(Date:12/17/2014)... YORK , Dec. 15, 2014  HITLAB SM ... (GCP) audit to confirm its adherence to current U.S. ... HITLAB to conduct regulated smart device and smart phone ... and research quality. "HITLAB is determined to ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... disorders are almost five times more common among boys than ... $15 million National Institutes of Health (NIH) grant awarded to ... (ACE) research program. Led by principal investigator Kevin ... is part of a $100 million National Institutes of Health ...
... - Influenza outbreaks in the United States typically begin ... spread in seasonal waves across geographic zones. But the ... to the next has baffled scientists. In a ... Obscure Consequence," Elena Naumova, Ph.D., professor of civil and ...
... SAN FRANCISCO, Sept. 6, 2012 -- After last year,s accidental ... State researchers are conducting an elaborate experiment to learn more ... are tagging infected bees with tiny radio trackers, and monitoring ... hive on top of the Hensill Hall biology building on ...
Cached Biology News:Influenza research: Can dynamic mapping reveal clues about seasonality? 2SF State biologists tag 'zombees' to track their flight 2SF State biologists tag 'zombees' to track their flight 3
... Monoclonal Mouse Antibody to Cytokeratin 5 ... is a high molecular weight, basic type ... and the superficial cell layers of stratified ... epithelia and in mesothelial cells and mesothelioma. ...
...
Aldolase A (N-15)...
Bovine Renal Artery Endothelial Cells (BRAEC) (>500,000 cells)...
Biology Products: